Talniflumate is a calcium-activated chloride channel (hCLCA1/mCLCA3) blocker that reduces mucin synthesis and release in animal models and cell culture. Talniflumate possesses anti-inflammatory actions via inhibition of Cox (cyclooxygenase) and inhibits Cl-/HCO3- exchange activity. Talniflumate increases survival in a cystic fibrosis mouse model of distal intestinal obstructive syndrome.